
[Shutterstock]
Novartis is acquiring a biotechnology company whose core is made up of a team of Greek scientists, for $1.7 billion.
Based in San Diego, California, Regulus Therapeutics specializes in the development of microRNA therapies. Its development of a microRNA drug candidate for kidney diseases that is currently in the clinical trial phase played a decisive role in the agreement with the Swiss pharma giant.
Interestingly, the main protagonists of Regulus Therapeutics are Greek scientists in the field of biotechnology who have excelled as leaders in large companies internationally and have been trying, in recent years, to build bridges of communication with Greece.